We are 2-Methoxy-5-methyl-N,N-bis(1-methylethyl)-3-phenylbenzenepropanamine fumarate CAS:124935-89-3 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 2-Methoxy-5-methyl-N,N-bis(1-methylethyl)-3-phenylbenzenepropanamine fumarate
Tolterodine Fumarate Tolterodine Fumarate
N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropanamine hydrogen fumarate
Molecular Weight: 455.58600
Physical and Chemical Properties:
Boiling point: /
Flash point: /
Refractive index: /
Appearance: White crystalline powder
Loss on Drying:NMT 0.5%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Tolterodine CAS:124937-51-5
Intermediates of Tolterodine tartrate CAS:124937-52-6
Related News: ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.4- (trifluorometoxi) fenil clorotioformiato CAS:2251-66-3 Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.25-97-8 Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.(4-Butoxy-2,3-difluorophenyl)boronic acid CAS:156487-12-6 Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.